Let's re­think Clin­ton's war on phar­ma; The FDA can't or­der the ge­nie back in­to the mag­ic lamp

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

 Sur­vey says!

Ever since I first start­ed think­ing about part­ner­ing up with Ar­salan Arif on End­points News, I want­ed to do a quar­ter­ly sur­vey of a sub­stan­tial num­ber of biotech ex­ecs to keep my thumb on the in­dus­try’s pulse. Now, 4 months from our launch, we did the first E100 sur­vey that found the pulse is quite strong. Yes, there is some flut­ter­ing ev­i­dent when you bring up top­ics like fu­ture fi­nanc­ings, IPOs, ac­cess to tal­ent, and so on. But by and large, biotechs are ex­pand­ing their teams and plan­ning to go in­to 2017 with am­bi­tious plans. We’ll fol­low up with a spe­cial 2017 fore­cast in Jan­u­ary. No one knows this in­dus­try bet­ter than the E100 com­bined. And you won’t want to miss what they have to say in the fu­ture.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE